Barrett's Esophagus — CPB 0728 | AETNA Coverage Update

Aetna modified CPB 0728 for Barrett's esophagus, effective November 27, 2025. Here's what billing teams need to know about covered procedures, experimental designations, and the long list of non-covered diagnostic tests.

Aetna, a CVS Health company, updated CPB 0728 — its Barrett's esophagus coverage policy — with a significant expansion of technologies it considers experimental, investigational, or unproven. The policy governs reimbursement for procedures billed under CPT codes including 43229, 43270, 43211, 43254, and 96570 (photodynamic therapy), along with a growing list of molecular and imaging codes that are now explicitly excluded. If your gastroenterology or thoracic surgery practice bills Aetna for Barrett's esophagus treatment or surveillance, this update directly affects your charge capture and prior authorization workflows.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Barrett's Esophagus — CPB 0728
Policy Code	CPB 0728
Change Type	Modified
Effective Date	November 27, 2025
Impact Level	High
Specialties Affected	Gastroenterology, Thoracic Surgery, General Surgery, Pathology/Molecular Diagnostics
Key Action	Audit claims for experimental-designated codes (especially molecular biomarker panels and AI-assisted detection) and remove them from your Barrett's esophagus billing workflows before submitting against this updated policy

---

Aetna Barrett's Esophagus Coverage Criteria and Medical Necessity Requirements 2025

The core medical necessity criteria in CPB 0728 are tiered by dysplasia grade. Get the grade wrong on a claim, and you'll get a denial.

For low-grade dysplasia (LGD), Aetna covers radiofrequency ablation (RFA) — but only when histological confirmation comes from two or more endoscopies at least three months apart. One biopsy is not enough. The documentation requirement is specific, and missing it is the most common reason these claims fail.

For high-grade dysplasia (HGD), confirmed by biopsy, Aetna considers five interventions medically necessary: endoscopic mucosal resection (CPT 43211 and 43254), esophagectomy (CPT codes 43107 through 43288), fundoplication (CPT 43279, 43280, 43325, 43327, 43328), photodynamic therapy (CPT +96570, +96571 with J9600 for porfimer sodium), and radiofrequency ablation (CPT 43229, 43270). The HGD pathway has more covered options, but each still requires biopsy confirmation in the medical record.

This coverage policy does not explicitly list prior authorization requirements within CPB 0728 itself — but RFA and esophagectomy are high-cost procedures that routinely trigger prior auth review under Aetna's utilization management programs. Check Aetna's prior authorization lookup tool for the specific CPT codes before scheduling. Assuming auth isn't required on a procedure this costly is a fast way to a claim denial.

---

Aetna Barrett's Esophagus Exclusions and Non-Covered Indications

This is where CPB 0728 gets expensive if your billing team isn't current on the policy. The list of experimental, investigational, or unproven designations is long — and several of them involve codes that labs and specialty practices have been billing with some frequency.

Ablation and surgical interventions that Aetna deems experimental include argon plasma coagulation (including hybrid APC), cryotherapy/cryoablation, laser therapy, multi-polar electrocoagulation, and ultrasonic therapy. If your endoscopist performs hybrid APC for Barrett's, you do not have a covered procedure under this policy. That's a significant clinical-coverage gap, and it's worth a conversation with your medical director.

Molecular and biomarker testing is where the real financial exposure sits in 2025. Aetna explicitly excludes:

CPT 0386U and 0398U — the P16, RUNX3, HPP1, and FBN1 methylation panels — are explicitly listed as not covered for indications in this CPB. If your lab is billing these, stop and review before the next claim goes out.

Imaging and endoscopic technologies classified as experimental include confocal laser endomicroscopy (CPT 43206, 43252), volumetric laser endomicroscopy, optical coherence tomography, and capsule endoscopy for Barrett's management (CPT 91110, 91111). The Cytosponge device also has no covered code under this policy — HCPCS Q0083, Q0084, and Q0085 (listed under Cytosponge) are not covered here.

Artificial intelligence for detection of early neoplasia in Barrett's esophagus is explicitly experimental. If your endoscopy center uses AI-assisted detection software and bills CPT 0108U for digital image analysis, Aetna will not cover it under this policy.

---

Coverage Indications at a Glance

---

Aetna Barrett's Esophagus Billing Guidelines and Action Items 2025

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Barrett's Esophagus Under CPB 0728

Covered CPT Codes (When Selection Criteria Are Met)

Covered HCPCS Codes (When Selection Criteria Are Met)

Code	Description Copy
J9600	Injection, porfimer sodium, 75 mg

Not Covered / Experimental CPT Codes

Not Covered HCPCS Codes

Code	Description	Reason Copy
Q0083	Chemotherapy administration	Cytosponge — no specific covered code under CPB 0728
Q0084	Chemotherapy administration	Cytosponge — no specific covered code under CPB 0728
Q0085	Chemotherapy administration	Cytosponge — no specific covered code under CPB 0728

Key ICD-10-CM Diagnosis Codes

---